Drug intelligence / Profile preview

AI-307

Development stage: Preclinical
Lead developer: Apeximmune Therapeutics
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

AI-307 is a recombinant protein therapeutic being developed by Apeximmune for the treatment of autoimmune diseases. It is designed to modulate immune responses by targeting AIM-103, a proprietary target identified by the developer. While Apeximmune is also developing AI-306, a monoclonal antibody targeting AIM-103 for oncological indications, AI-307 utilizes a recombinant protein modality specifically tailored for immune-mediated inflammatory conditions. The drug is currently in the early stages of development within Apeximmune's pipeline.

Targets

AIM-103

Beyond the preview

Go deeper on AI-307.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AI-307.

Explore the full profile